338 related articles for article (PubMed ID: 28854810)
1. Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy.
Hagedorn C; Kreppel F
Hum Gene Ther; 2017 Oct; 28(10):820-832. PubMed ID: 28854810
[TBL] [Abstract][Full Text] [Related]
2. Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.
Jönsson F; Hagedorn C; Kreppel F
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30417881
[TBL] [Abstract][Full Text] [Related]
3. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
4. Methods for Modification of Therapeutic Viruses.
Hill CAP; Bau L; Carlisle R
Methods Mol Biol; 2020; 2058():7-29. PubMed ID: 31486029
[TBL] [Abstract][Full Text] [Related]
5. Chapter four--Design of improved oncolytic adenoviruses.
Alemany R
Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
[TBL] [Abstract][Full Text] [Related]
6. Concepts in Oncolytic Adenovirus Therapy.
Mantwill K; Klein FG; Wang D; Hindupur SV; Ehrenfeld M; Holm PS; Nawroth R
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638863
[TBL] [Abstract][Full Text] [Related]
7. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in genetic modification of adenovirus vectors for cancer treatment.
Yamamoto Y; Nagasato M; Yoshida T; Aoki K
Cancer Sci; 2017 May; 108(5):831-837. PubMed ID: 28266780
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.
Kim J; Li Y; Kim SW; Lee DS; Yun CO
Biomaterials; 2013 Jun; 34(19):4622-31. PubMed ID: 23541109
[TBL] [Abstract][Full Text] [Related]
10. Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions.
Weklak D; Pembaur D; Koukou G; Jönsson F; Hagedorn C; Kreppel F
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372506
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic viruses: adenoviruses.
Niemann J; Kühnel F
Virus Genes; 2017 Oct; 53(5):700-706. PubMed ID: 28702840
[TBL] [Abstract][Full Text] [Related]
13. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.
Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F
J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065
[TBL] [Abstract][Full Text] [Related]
14. Introduction to Oncolytic Virotherapy.
Engeland CE; Bell JC
Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
[TBL] [Abstract][Full Text] [Related]
15. Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5
Davies JA; Marlow G; Uusi-Kerttula HK; Seaton G; Piggott L; Badder LM; Clarkson RWE; Chester JD; Parker AL
Viruses; 2021 May; 13(5):. PubMed ID: 34066836
[TBL] [Abstract][Full Text] [Related]
16. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.
Cerullo V; Koski A; Vähä-Koskela M; Hemminki A
Adv Cancer Res; 2012; 115():265-318. PubMed ID: 23021247
[TBL] [Abstract][Full Text] [Related]
17. Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.
Heiniö C; Sorsa S; Siurala M; Grönberg-Vähä-Koskela S; Havunen R; Haavisto E; Koski A; Hemminki O; Zafar S; Cervera-Carrascon V; Munaro E; Kanerva A; Hemminki A
Hum Gene Ther; 2019 Jun; 30(6):740-752. PubMed ID: 30672366
[TBL] [Abstract][Full Text] [Related]
18. Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?
Bots STF; Hoeben RC
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650405
[TBL] [Abstract][Full Text] [Related]
19. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
20. Tumor Targeting of Oncolytic Adenoviruses Using Bispecific Adapter Proteins.
Niemann J; Kühnel F
Methods Mol Biol; 2020; 2058():31-49. PubMed ID: 31486030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
